ClinicalTrials.gg
CompletedNCT05215977Updated Oct 11, 2023

Efficacy and Safety of MW031 in PMO Subjects

A Phase 3 interventional study of MW031 and Placebo in Osteoporosis, Postmenopausal, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Completed at 1 site in China. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Dec 2019, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
9th of 31
448 · median 278
Started
2019
with 3 others
Phase 3
17 of 31
1 open now
Registered
28th of 31
by date
Lead sponsor
2 of 31
Mabwell (Shanghai) Bioscience Co., Ltd.

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 17 in phase 3, and was the 28th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW031 in Chinese postmenopausal osteoporotic subjects with increased bone fracture risk .

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BMD -4.0\<T-score ≤-2.5 at either the lumbar spine or total hip or femoral neck
  • All subjects must have at least one of following additional the risk factors:history of fracture, parental history of hip fracture, increased bone turnover rate at screening, low body weight, elderly (age≥65year),current smoker
  • is defined as >2 years postmenopausal, which can be >2 years of spontaneous amenorrhea, or bilateral oophorectomy >2 years after surgery. If bilateral oophorectomy status is unknown, use follicle-stimulating hormone (FSH) levels > 40 mIU/mL to confirm surgical postmenopausal status.

Exclusion criteria

Exclusion Criteria:

  • Bone/metabolic disease
  • Hyperparathyroidism or hypoparathyroidism
  • Thyroid condition: Hyperthyroidism or hypothyroidism
  • Rheumatoid arthritis
  • Malignant tumors
  • Malabsorption syndrome
  • Oral bisphosphonates
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Experimental
    MW031

    MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.

    Drug: MW031

  • Placebo comparator
    placebo

    Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

    Drug: Placebo

Interventions

  • DrugMW031

    The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial. Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU

    Also known as: Recombinant anti-RANKL human monoclonal antibody injection

  • DrugPlacebo

    subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial. Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU

06

What researchers measure

Primary outcomes

  1. Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine from Baseline up to 12 months

    Dual energy x-ray absorptiometry (DXA) is applied for Bone mineral density (BMD) assessment.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Percent Change in BMD at the Lumbar Spine from Baseline up to 6 months

    Time frame: Baseline and Month 6

  2. Percent change in BMD at the total hip, femoral neck from Baseline up to 6 months and 12 months

    Time frame: Baseline, Month 6 and Month 12

  3. Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type I N Propeptideserum (s-PINP) from Baseline up to 12 months

    Time frame: Baseline, Month 1, Month 3, Month 6, Month 9 and Month 12

07

Study locations

1 site
  • Peking Union Hospital
    Beijing, Beijing 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2021, 21 months.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 21 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2022
First posted
Jan 31, 2022
StartActual
Dec 27, 2019
Primary completionActual
Sep 27, 2021
CompletionActual
Sep 27, 2021
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05215977
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Dec 27, 2019
Primary completion
Sep 27, 2021
Completion
Sep 27, 2021
Last update
Oct 11, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion